[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100535698":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":29,"locations":39,"responsibleParty":69,"collaborators":20,"id":73,"slug":74,"hasResults":75,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":75,"sex":81,"minAge":82,"maxAge":20,"enrollmentInfo":83,"targetDuration":20,"studyType":86,"phases":87,"briefSummary":89,"conditions":90,"keywords":92,"overallStatus":41,"whyStopped":20,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":103},{"fullName":5,"class":6},"Eye & ENT Hospital of Fudan University","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Induction chemotherapy in different subtypes of olfactory neuroblastoma","EXPERIMENTAL","Induction chemotherapy based on pathological molecular subtypes of olfactory neuroblastoma.\n\n① According to the immunohistochemical results of the pathological report, patients with Ki-67 index ≥ 25% were treated with two weeks of gemcitabine+platinum based chemotherapy regimen;\n\n② According to the immunohistochemical results of the pathological report, patients with Ki-67 index \\\u003C25% were treated with a basic chemotherapy regimen of cyclophosphamide+etoposide+cisplatin (CEP regimen);\n\nAccording to the progression of the patient's disease, the combination of other chemotherapy\u002Fsmall molecule drugs\u002Ftargeted drugs can be considered;",[13],"Drug: Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DRUG","Gemcitabine+Cisplatin(GP); Cyclophosphamide+Etoposide+Cisplatin(CEP)","When the Ki67% index of the tumor is ≥ 25%, patients were treated with the GP regimen for induction chemotherapy; When the Ki67% index of the tumor is \\\u003C 25%, patients were treated with the CEP regimen for induction chemotherapy.",[9],null,[22,26],{"name":23,"affiliation":24,"role":25},"Hongmeng Yu, Prof.","Eye & ENT Hospital, Fudan University","PRINCIPAL_INVESTIGATOR",{"name":27,"affiliation":24,"role":28},"Xicai Sun, MD","STUDY_DIRECTOR",[30,35],{"name":31,"role":32,"phone":33,"phoneExt":20,"email":34},"Xiaole Song, MD","CONTACT","15821388769","jxfxsxl@163.com",{"name":36,"role":32,"phone":37,"phoneExt":20,"email":38},"Jingyi Yang, MD","19529941927","yangjingyi_ent@163.com",[40],{"facility":5,"status":41,"city":42,"state":43,"zip":44,"country":45,"countryCode":46,"cosmosGeoPoint":47,"geoPoint":52,"contacts":53},"RECRUITING","Shanghai","Shanghai Municipality","200031","China","CN",{"type":48,"coordinates":49},"Point",[50,51],121.45806,31.22222,{"lat":51,"lon":50},[54,58,60,61,64,65,67],{"name":55,"role":32,"phone":56,"phoneExt":20,"email":57},"Hongmeng Yu, Dr","13501730576","hongmengyush@fudan.edu.cn",{"name":59,"role":32,"phone":33,"phoneExt":20,"email":34},"Xiaole Song, Dr",{"name":55,"role":25,"phone":20,"phoneExt":20,"email":20},{"name":62,"role":63,"phone":20,"phoneExt":20,"email":20},"Xicai Sun, Dr","SUB_INVESTIGATOR",{"name":59,"role":63,"phone":20,"phoneExt":20,"email":20},{"name":66,"role":63,"phone":20,"phoneExt":20,"email":20},"Jingyi Yang, Dr",{"name":68,"role":63,"phone":20,"phoneExt":20,"email":20},"Fu Chen, Dr",{"type":70,"investigatorFullName":71,"investigatorTitle":72,"investigatorAffiliation":5,"oldNameTitle":20,"oldOrganization":20},"SPONSOR_INVESTIGATOR","Hongmeng Yu","Professor","100535698","phase-2-efficacy-and-safety-of-induction-chemotherapy-for-olfactory-neuroblastoma-esicon-100535698",false,"NCT06255210","Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON)","Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma: a Prospective Umbrella Clinical Study","ESICON","Inclusion Criteria:\n\n1. Patients with pathologically confirmed olfactory neuroblastoma;\n2. Age ≥ 18 years old;\n3. Dulguerov stage T2-T4;\n4. Patients who signed the informed consent forms;\n5. No distant metastasis.\n\nExclusion Criteria:\n\n1. Patients with uncontrolled concurrent diseases that the researchers believe will interfere with treatment;\n2. Any situation in which the patient may interfere with the compliance or safety during the study;\n3. Severe neurological or mental illness, including dementia and seizures;\n4. Uncontrolled active infection;\n5. Pregnant or lactating women;\n6. Persons without personal freedom and independent capacity for civil conduct;\n7. Other situations that are not suitable for joining the group.","ALL","18 Years",{"count":84,"type":85},25,"ESTIMATED","INTERVENTIONAL",[88],"PHASE2","The goal of this clinical trial is to learn about the induction chemotherapy efficacy in olfactory neuroblastoma. The main question it aims to answer is: wether olfactory neuroblastoma patients with different pathology subtypes apply to different induction chemotherapy schemes. Participants will be treated with different chemotherapy schemes, to evaluate the tumor remission rate and long term survival.",[91],"Olfactory Neuroblastoma",[93],"Induction Chemotherapy","2024-02-04",{"date":96,"type":97},"2024-02-13","ACTUAL",{"date":99,"type":85},"2024-03-01",{"date":101,"type":85},"2030-03-01",{"name":71,"class":6},1]